Travere Therapeutics (TVTX) Misses Q1 EPS by 17c

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.40), $0.17 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $127.2 million versus the consensus estimate of $137.34 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Irenic Capital opposes Independence Realty's Centerspace deal - Bloomberg
• Faraday Future plans robotics spinoff with AIxC at $200M valuation
• Bernstein SocGen Group Upgrades Solaria Energia y Medio Ambiente SA (SLR:SM) to Outperform